217 related articles for article (PubMed ID: 38646524)
1. Modulation of the skin microbiome in cutaneous T-cell lymphoma delays tumour growth and increases survival in the murine EL4 model.
Dey S; Vieyra-Garcia PA; Joshi AA; Trajanoski S; Wolf P
Front Immunol; 2024; 15():1255859. PubMed ID: 38646524
[TBL] [Abstract][Full Text] [Related]
2. Extracorporeal photophoresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
[TBL] [Abstract][Full Text] [Related]
3. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis.
Nevala H; Karenko L; Vakeva L; Ranki A
Br J Dermatol; 2001 Dec; 145(6):928-37. PubMed ID: 11899146
[TBL] [Abstract][Full Text] [Related]
4. Narrowband ultraviolet B response in cutaneous T-cell lymphoma is characterized by increased bacterial diversity and reduced
Hooper MJ; Enriquez GL; Veon FL; LeWitt TM; Sweeney D; Green SJ; Seed PC; Choi J; Guitart J; Burns MB; Zhou XA
Front Immunol; 2022; 13():1022093. PubMed ID: 36439132
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiota analyses of cutaneous T-cell lymphoma patients undergoing narrowband ultraviolet B therapy reveal alterations associated with disease treatment.
Nguyen WQ; Chrisman LP; Enriquez GL; Hooper MJ; Griffin TL; Ahmad M; Rahman S; Green SJ; Seed PC; Guitart J; Burns MB; Zhou XA
Front Immunol; 2023; 14():1280205. PubMed ID: 38274799
[TBL] [Abstract][Full Text] [Related]
6. Management of refractory early-stage cutaneous T-cell lymphoma.
Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
[TBL] [Abstract][Full Text] [Related]
7. A novel mouse model of cutaneous T-cell lymphoma revealed the combined effect of mogamulizumab with psoralen and ultraviolet a therapy.
Nakahashi K; Nihira K; Suzuki M; Ishii T; Masuda K; Mori K
Exp Dermatol; 2022 Nov; 31(11):1693-1698. PubMed ID: 35801380
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
9. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional Heterogeneity and the Microbiome of Cutaneous T-Cell Lymphoma.
Licht P; Mailänder V
Cells; 2022 Jan; 11(3):. PubMed ID: 35159138
[TBL] [Abstract][Full Text] [Related]
11. Methicillin-resistant Staphylococcus aureus (MRSA) is an important pathogen in erythrodermic cutaneous T-cell lymphoma (CTCL) patients.
Emge DA; Bassett RL; Duvic M; Huen AO
Arch Dermatol Res; 2020 May; 312(4):283-288. PubMed ID: 31776647
[TBL] [Abstract][Full Text] [Related]
12. Enterococcal eschars in cutaneous T-cell lymphoma tumors: a distinct clinical entity.
Duvic M; Feasel AM; Schwartz CA; Cather JC
Clin Lymphoma; 2000 Sep; 1(2):141-5. PubMed ID: 11707823
[TBL] [Abstract][Full Text] [Related]
13. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.
Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S
J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782
[TBL] [Abstract][Full Text] [Related]
14. Antibiotics and Imiquimod for Cutaneous T-Cell Lymphoma in Veterans: A Patient Population with Agent Orange Exposure.
Del Guzzo CA; Kojadinovic A; Vinnakota RR; Geskin LJ; Newman JC; Langhoff E; Park YA; Bates SE; Dana AN
Oncologist; 2021 Sep; 26(9):727-e1488. PubMed ID: 33851477
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of bexarotene combined with photo(chemo)therapy for cutaneous T-cell lymphoma.
Morita A; Tateishi C; Muramatsu S; Kubo R; Yonezawa E; Kato H; Nishida E; Tsuruta D
J Dermatol; 2020 May; 47(5):443-451. PubMed ID: 32189402
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous manifestations of Epstein-Barr virus-associated T-cell lymphoma.
Su IJ; Tsai TF; Cheng AL; Chen CC
J Am Acad Dermatol; 1993 Nov; 29(5 Pt 1):685-92. PubMed ID: 8227539
[TBL] [Abstract][Full Text] [Related]
17. Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-κB.
Nicolay JP; Müller-Decker K; Schroeder A; Brechmann M; Möbs M; Géraud C; Assaf C; Goerdt S; Krammer PH; Gülow K
Blood; 2016 Aug; 128(6):805-15. PubMed ID: 27268084
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous T-cell lymphoma and Staphylococcus aureus colonization.
Nguyen V; Huggins RH; Lertsburapa T; Bauer K; Rademaker A; Gerami P; Guitart J
J Am Acad Dermatol; 2008 Dec; 59(6):949-52. PubMed ID: 18835065
[TBL] [Abstract][Full Text] [Related]
19. Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas.
Martin AG
J Drugs Dermatol; 2003 Apr; 2(2):155-67. PubMed ID: 12852367
[TBL] [Abstract][Full Text] [Related]
20. ECP versus PUVA for the treatment of cutaneous T-cell lymphoma.
Geskin L
Skin Therapy Lett; 2007 Jun; 12(5):1-4. PubMed ID: 17609808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
